Update shared on 12 Jan 2026
We now await the JP Morgan health conference . John Evans is set to speak on 13th January. The next big milestones for Beam has been the confirmation of RMAT , fast-track approval of Beam 302 today and the next big thing is the 302 data which will be after the JP Morgan Conference.
We also await many analysts covering Beam to update their pricing which is out of date and stale . This does not reflect the god-like data presented in 101 from Ash 25 and the tailwinds for Beam in 2026 towards approval.
I see 45-55$ post JPM then maybe 65-75$ after 302 data.
Have other thoughts on Beam Therapeutics?
Create your own narrative on this stock, and estimate its Fair Value using our Valuator tool.
Create NarrativeDisclaimer
The user davidlsander has a position in NasdaqGS:BEAM. Simply Wall St has no position in any of the companies mentioned. Simply Wall St may provide the securities issuer or related entities with website advertising services for a fee, on an arm's length basis. These relationships have no impact on the way we conduct our business, the content we host, or how our content is served to users. The author of this narrative is not affiliated with, nor authorised by Simply Wall St as a sub-authorised representative. This narrative is general in nature and explores scenarios and estimates created by the author. The narrative does not reflect the opinions of Simply Wall St, and the views expressed are the opinion of the author alone, acting on their own behalf. These scenarios are not indicative of the company's future performance and are exploratory in the ideas they cover. The fair value estimates are estimations only, and does not constitute a recommendation to buy or sell any stock, and they do not take account of your objectives, or your financial situation. Note that the author's analysis may not factor in the latest price-sensitive company announcements or qualitative material.